Marketing authorisation for sibutramine has been suspended following a review by the European Medicines Agency. The benefits do not outweigh the cardiovascular risks. Prescriptions should not be issued for it and pharmacists will not dispense them.
It takes some time for new drugs to become available and licensed because serious side effects may not appear immediately. If they appear after licensing they can still be withdrawn. Fads and unlicensed drugs rely on marketing and anecdotes, not proper trials. Buy the mug, not the coffee
